SMT201400096B - Immidazoli fusi e composizioni che li comprendono per il trattamento di malattie parassitarie, come ad esempio la malaria - Google Patents

Immidazoli fusi e composizioni che li comprendono per il trattamento di malattie parassitarie, come ad esempio la malaria

Info

Publication number
SMT201400096B
SMT201400096B SM201400096T SM201400096T SMT201400096B SM T201400096 B SMT201400096 B SM T201400096B SM 201400096 T SM201400096 T SM 201400096T SM 201400096 T SM201400096 T SM 201400096T SM T201400096 B SMT201400096 B SM T201400096B
Authority
SM
San Marino
Prior art keywords
immidazoles
malaria
melted
compositions
treatment
Prior art date
Application number
SM201400096T
Other languages
English (en)
Italian (it)
Inventor
Arnab K Chatterjee
Advait Nagle
Tao Wu
David Tully
Kelli L Kuhen
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42727573&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT201400096(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Irm Llc filed Critical Irm Llc
Publication of SMT201400096B publication Critical patent/SMT201400096B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541Non-condensed thiazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/022Boron compounds without C-boron linkages
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SM201400096T 2009-07-09 2014-07-22 Immidazoli fusi e composizioni che li comprendono per il trattamento di malattie parassitarie, come ad esempio la malaria SMT201400096B (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22443309P 2009-07-09 2009-07-09
PCT/US2010/041626 WO2011006143A2 (en) 2009-07-09 2010-07-09 Compounds and compositions for the treatment of parasitic diseases

Publications (1)

Publication Number Publication Date
SMT201400096B true SMT201400096B (it) 2014-09-08

Family

ID=42727573

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201400096T SMT201400096B (it) 2009-07-09 2014-07-22 Immidazoli fusi e composizioni che li comprendono per il trattamento di malattie parassitarie, come ad esempio la malaria

Country Status (38)

Country Link
US (3) US8557801B2 (uk)
EP (2) EP2451814B1 (uk)
JP (1) JP5432376B2 (uk)
KR (1) KR101378666B1 (uk)
CN (1) CN102471341B (uk)
AR (1) AR077463A1 (uk)
AU (1) AU2010271247B2 (uk)
BR (1) BR112012000413B1 (uk)
CA (1) CA2767664C (uk)
CL (1) CL2012000042A1 (uk)
CO (1) CO6491060A2 (uk)
CR (1) CR20120008A (uk)
CU (1) CU24155B1 (uk)
DK (1) DK2451814T3 (uk)
EA (1) EA019655B1 (uk)
EC (1) ECSP12011585A (uk)
ES (2) ES2477940T3 (uk)
GT (1) GT201200004A (uk)
HK (1) HK1164304A1 (uk)
HN (1) HN2012000023A (uk)
HR (1) HRP20140641T1 (uk)
IL (1) IL217384A (uk)
JO (1) JO3156B1 (uk)
MA (1) MA33419B1 (uk)
MX (1) MX2012000389A (uk)
MY (1) MY157238A (uk)
NZ (1) NZ597275A (uk)
PE (1) PE20130399A1 (uk)
PL (1) PL2451814T3 (uk)
PT (1) PT2451814E (uk)
SG (1) SG176938A1 (uk)
SI (1) SI2451814T1 (uk)
SM (1) SMT201400096B (uk)
TN (1) TN2011000647A1 (uk)
TW (1) TWI421252B (uk)
UA (1) UA103930C2 (uk)
UY (1) UY32776A (uk)
WO (1) WO2011006143A2 (uk)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2015118985A (ru) 2012-11-14 2017-01-10 Ф. Хоффманн-Ля Рош Аг Производные имидазопиридина
EP2920177A1 (en) * 2012-11-19 2015-09-23 Novartis AG Compounds and compositions for the treatment of parasitic diseases
US8871754B2 (en) 2012-11-19 2014-10-28 Irm Llc Compounds and compositions for the treatment of parasitic diseases
CN105164124B (zh) * 2012-11-19 2017-03-15 诺华股份有限公司 用于治疗寄生虫疾病的化合物和组合物
CN103126782B (zh) * 2013-02-26 2016-06-29 内蒙古农牧业科学院 一种寄生病的治疗方法
PE20160865A1 (es) * 2013-12-19 2016-09-03 Novartis Ag Derivados de [1,2,4] triazolo [1,5-a]pirimidina como inhibidores de proteasoma para el tratamiento de enfermedades parasitarias tales como leishmaniasis
JP6847942B2 (ja) * 2015-07-31 2021-03-24 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung 二環式複素環式誘導体
MA45918A (fr) * 2016-08-15 2019-06-19 Bayer Ag Dérivés hétérocycliques bicycliques condensés utilisés comme pesticides
EP3615030A1 (en) 2017-04-24 2020-03-04 Novartis AG Therapeutic regimen of 2-amino-l-(2-(4-fluorophenyl)-3-(4-fluorophenylamino)-8,8-dimethyl-5,6-dihydroimidazo[1,2-a]pyrazin-7(8h)-yl)ethanone and combinations thereof
IL271981B (en) 2017-07-14 2022-09-01 Hoffmann La Roche Bicyclic ketone compounds and methods of using them
US11530209B2 (en) * 2017-10-04 2022-12-20 Dana-Farber Cancer Institute, Inc. Small molecule inhibition of transcription factor SALL4 and uses thereof
WO2022049548A1 (en) 2020-09-04 2022-03-10 Novartis Ag Kaf156 combinations and methods for the treatment of malaria
WO2023168107A2 (en) * 2022-03-04 2023-09-07 University Of Central Florida Research Foundation, Inc. Compounds and compositions for anitmalarial therapeutic and prophylactic use
CN114569711B (zh) * 2022-03-24 2024-04-19 安徽医科大学 一种预防弓形虫病的ME49Δcdpk3减毒活疫苗及其制备方法和应用
WO2024006970A2 (en) * 2022-07-01 2024-01-04 The Scripps Research Institute Antimalarial compounds
WO2024006974A2 (en) * 2022-07-01 2024-01-04 The Scripps Research Institute Antimalarial compounds
WO2024006971A2 (en) * 2022-07-01 2024-01-04 The Scripps Research Institute Antimalarial compounds

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK476885D0 (da) 1985-10-17 1985-10-17 Ferrosan As Heterocycliske forbindelser og fremgangsmaader til fremstilling heraf
US6673927B2 (en) 1996-02-16 2004-01-06 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Farnesyl transferase inhibitors
CA2334945A1 (en) 1998-06-12 1999-12-16 Christophe Alain Thurieau Imidazolyl derivatives
FR2780974B1 (fr) 1998-07-08 2001-09-28 Sod Conseils Rech Applic Utilisation de derives d'imidazopyrazines pour preparer un medicament destine a traiter les pathologies qui resultent de la formation de la proteine g heterotrimetrique
DE69915514T2 (de) 1998-12-31 2005-01-05 Société de Conseils de Recherches et d'Applications Scientifiques S.A.S. Prenyltransferase-inhibitoren
EP1233787B8 (fr) 1999-11-09 2005-05-18 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Produit comprenant un inhibiteur de la transduction des signaux des proteines g heterotrimeriques en association avec un autre agent anti-cancereux pour une utilisation therapeutique dans le traitement du cancer
FR2803525B1 (fr) 2000-01-06 2002-05-03 Sod Conseils Rech Applic Inhibiteur de la transduction des signaux des proteines g heterotrimeriques associe a un agent anti-hypertenseur dans le traitement de l'hypertension arterielle
KR20030020960A (ko) 2000-08-01 2003-03-10 소시에떼 더 콘세이유 더 레세르세 에 다플리까띠옹 시엔띠피끄, 에스.아.에스. 이미다졸일 유도체
EP1363899B1 (en) * 2001-01-02 2005-05-11 F.Hoffmann-La Roche Ag Quinazolone derivatives as alpha 1a/b adrenergic receptor antagonists
FR2825278A1 (fr) 2001-05-30 2002-12-06 Sod Conseils Rech Applic Produit comprenant du mikanolide, du dihydromikanolide ou un analogue de ceux-ci en association avec un autre agent anti-cancereux pour une utilisation therapeutique dans le traitement du cancer
UA74912C2 (en) * 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US7307164B2 (en) 2002-03-25 2007-12-11 Merck & Co., Inc. β-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
US20060166907A1 (en) 2002-09-27 2006-07-27 Gregoire Prevost Composition for the treatment of nasopharyngeal carcinoma and method of use thereof
US20040209897A1 (en) 2002-12-20 2004-10-21 Pharmacia Corporation Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds
US20060052382A1 (en) * 2002-12-20 2006-03-09 Duffy Joseph L 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
CA2517427C (en) * 2003-03-06 2012-07-24 Merck & Co., Inc. Antiprotozoal imidazopyridine compounds
AR043633A1 (es) 2003-03-20 2005-08-03 Schering Corp Ligandos de receptores de canabinoides
DE602004023932D1 (de) 2003-05-14 2009-12-17 Merck & Co Inc 3-amino-4-phenylbutansäurederivate als dipeptidylpeptidase-hemmer zur behandlung oder vorbeugung von diabetes
FR2856688B1 (fr) 2003-06-25 2008-05-30 Sod Conseils Rech Applic PRODUIT COMPRENANT AU MOINS UN INHIBITEUR DE PHOSPHATASE CDc25 EN ASSOCIATION AVEC AU MOINS UN AUTRE AGENT ANTI-CANCEREUX
FR2867778B1 (fr) * 2004-03-16 2006-06-09 Sanofi Synthelabo Utilisation de derives d'indazolecarboxamides pour la preparation d'un medicament destine au traitement et a la prevention du paludisme
KR20100114944A (ko) 2005-08-11 2010-10-26 에프. 호프만-라 로슈 아게 Dpp-iv 억제제를 포함하는 약학 조성물
RU2318818C1 (ru) 2006-04-12 2008-03-10 Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" Азагетероциклы, комбинаторная библиотека, фокусированная библиотека, фармацевтическая композиция и способ получения (варианты)
WO2007124423A2 (en) 2006-04-21 2007-11-01 Smithkline Beecham Corporation Il-8 receptor antagonists
US20120142623A1 (en) 2006-07-07 2012-06-07 Michael Lagunoff Compositions And Methods For Predicting Inhibitors Of Protein Targets
TW200808056A (en) * 2006-07-26 2008-02-01 Compal Communications Inc Rear projection display system
AU2008210904A1 (en) * 2007-01-26 2008-08-07 Irm Llc Purine compounds and compositions as kinase inhibitors for the treatment of Plasmodium related diseases
US20080242862A1 (en) * 2007-03-27 2008-10-02 Calderwood David J Novel imidazo based heterocycles
WO2009005675A1 (en) 2007-06-28 2009-01-08 Abbott Laboratories Novel triazolopyridazines
CN101357922B (zh) 2007-08-02 2011-05-18 山东轩竹医药科技有限公司 新的dpp-iv抑制剂
EP2085398A1 (en) 2008-02-01 2009-08-05 Merz Pharma GmbH & Co. KGaA Pyrazolopyrimidines, a process for their preparation and their use as medicine
EP2090576A1 (en) 2008-02-01 2009-08-19 Merz Pharma GmbH & Co.KGaA 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators
EP2300466B1 (en) 2008-06-20 2014-08-06 Bristol-Myers Squibb Company Imidazopyridine and imidazopyrazine compounds useful as kinase inhibitors

Also Published As

Publication number Publication date
TN2011000647A1 (en) 2013-05-24
CR20120008A (es) 2012-03-12
IL217384A0 (en) 2012-02-29
GT201200004A (es) 2014-03-27
ES2574529T3 (es) 2016-06-20
US8557801B2 (en) 2013-10-15
CO6491060A2 (es) 2012-07-31
SI2451814T1 (sl) 2014-08-29
US9469645B2 (en) 2016-10-18
EA201200098A1 (ru) 2012-07-30
MX2012000389A (es) 2012-03-07
PE20130399A1 (es) 2013-04-06
DK2451814T3 (da) 2014-07-14
US9963454B2 (en) 2018-05-08
UY32776A (es) 2011-02-28
AU2010271247B2 (en) 2013-07-18
KR20120047939A (ko) 2012-05-14
EP2737927B1 (en) 2016-03-30
PL2451814T3 (pl) 2014-09-30
CA2767664A1 (en) 2011-01-13
PT2451814E (pt) 2014-07-16
ES2477940T3 (es) 2014-07-18
HRP20140641T1 (hr) 2014-09-26
ECSP12011585A (es) 2012-02-29
CA2767664C (en) 2013-12-10
EP2737927A1 (en) 2014-06-04
JP2012532890A (ja) 2012-12-20
HN2012000023A (es) 2014-08-18
WO2011006143A2 (en) 2011-01-13
US20130281403A1 (en) 2013-10-24
IL217384A (en) 2015-07-30
CU20120002A7 (es) 2012-06-21
JO3156B1 (ar) 2017-09-20
JP5432376B2 (ja) 2014-03-05
TW201105675A (en) 2011-02-16
SG176938A1 (en) 2012-01-30
AR077463A1 (es) 2011-08-31
MY157238A (en) 2016-05-13
BR112012000413A2 (pt) 2020-08-11
US20110059934A1 (en) 2011-03-10
AU2010271247A1 (en) 2012-01-19
CN102471341A (zh) 2012-05-23
BR112012000413B1 (pt) 2022-02-15
CU24155B1 (es) 2016-03-31
KR101378666B1 (ko) 2014-03-26
TWI421252B (zh) 2014-01-01
NZ597275A (en) 2013-05-31
UA103930C2 (uk) 2013-12-10
US20160108051A1 (en) 2016-04-21
HK1164304A1 (en) 2012-09-21
EA019655B1 (ru) 2014-05-30
WO2011006143A3 (en) 2011-06-09
EP2451814A2 (en) 2012-05-16
CL2012000042A1 (es) 2012-12-21
MA33419B1 (fr) 2012-07-03
EP2451814B1 (en) 2014-04-09
CN102471341B (zh) 2014-07-02

Similar Documents

Publication Publication Date Title
SMT201400096B (it) Immidazoli fusi e composizioni che li comprendono per il trattamento di malattie parassitarie, come ad esempio la malaria
SMT201600254B (it) Procedimento per la preparazione di idromagnesite
SMT201600049B (it) Formulazioni di apixaban
SMT201400071B (it) Composizione e procedimenti per l'inibizione dellavia di jak
DK2504005T3 (da) Anvendelse af 1,3-diphenylprop-2-en-1-on-derivater til behandling af lever-sygdomme
SMT201400160B (it) Nuove composizioni per il trattamento di cmt e malattie correlate
IT1397620B1 (it) Asta per occhiali ed occhiali comprendenti quest'asta
IT1391866B1 (it) Composizione iniettabile di polinucleotidi per il trattamento di patologie osteoarticolari.
SMT201400165B (it) Composizioni e metodi per il trattamento di sclerosi multipla
IL209360A (en) Medications containing pm00104 for the treatment of multiple myeloma
IT1400714B1 (it) Processo ed intermedi per la preparazione di un principio attivo.
ITTO20110268A1 (it) Composizione di maquillage.
IT1402446B1 (it) "composizione di birra "radoy" e suo metodo di produzione"
IT1403587B1 (it) Composizione per il trattamento di disordini metabolici
IT1397503B1 (it) Processo per la preparazione di olopatadina
IT1395118B1 (it) Procedimento per la preparazione di dexlansoprazolo cristallino
IT1405996B1 (it) Procedimento per la preparazione di 2,5-diaminotoluolo
ITTO20110857A1 (it) Procedimento per la produzione di cicloesanonossina.
IT1403988B1 (it) Processo per la preparazione di agenti di contrasto.
IT1394299B1 (it) Procedimento per la preparazione di sevelamer
IT1391776B1 (it) Procedimento per la preparazione di dexlansoprazolo
ITMI20080011A1 (it) Procedimento per la preparazione di diacereina
IT1398273B1 (it) Procedimento per la preparazione di 14-bromo daunomicina
IT1394407B1 (it) Procedimento per la preparazione di fosinopril e suoi intermedi
IT1406151B1 (it) Procedimento per la preparazione di fosinopril e suoi intermedi